Drug intelligence / Profile preview

IMM-005

Development stage: Preclinical
Lead developer: IMMvention Therapeutix
Modality: Small Molecules
Administration: Unknown (unspecified Route; Likely Non-biologic Routes Such As Oral Or Intravenous Based On Modality)[1]

Overview

IMM-005 is a new chemical entity under development by IMMvention Therapeutix for the treatment of neurodegenerative disorders. The drug is currently in preclinical or early research stages in the United States. Its precise mechanism of action has not been publicly defined as of June 2025. IMM-005 represents a novel approach to treating nervous system diseases and is available for licensing[1][2].

Beyond the preview

Go deeper on IMM-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMM-005.

Explore the full profile